Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal

Cost Effectiveness ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Adrenergic Agonist ◽

Muscarinic Antagonist ◽

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease

Cureus ◽

10.7759/cureus.19168 ◽

2021 ◽

Author(s):

Mizuki Yuasa ◽

Yosuke Tanaka ◽

Tohru Tanaka ◽

Takeru Kashiwada ◽

Namiko Taniuchi ◽

...

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Muscarinic Antagonist ◽

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012066.pub2 ◽

2017 ◽

Cited By ~ 18

Author(s):

Nobuyuki Horita ◽

Atsushi Goto ◽

Yuji Shibata ◽

Erika Ota ◽

Kentaro Nakashima ◽

...

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease

10.1002/14651858.cd012066 ◽

2016 ◽

Cited By ~ 2

Author(s):

Nobuyuki Horita ◽

Atsushi Goto ◽

Erika Ota ◽

Kentaro Nakashima ◽

Kenjiro Nagai ◽

...

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Switching from long‐acting beta‐agonist and inhaled corticosteroid to long‐acting beta‐agonist and long‐acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal

Internal Medicine Journal ◽

10.1111/imj.14931 ◽

2020 ◽

Vol 50 (S3) ◽

pp. 15-18

Author(s):

Jamie Chung Mei Lam

Keyword(s):

Case Report ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Corticosteroid Withdrawal ◽

Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1070826 ◽

2015 ◽

Vol 16 (13) ◽

pp. 2009-2021 ◽

Cited By ~ 11

Author(s):

Girolamo Pelaia ◽

Carmelo Caio Muzzio ◽

Alessandro Vatrella ◽

Rosario Maselli ◽

Maria Sandra Magnoni ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Adrenergic Agonist ◽

Disease Treatment ◽

Long Acting ◽

Scientific Rationale ◽

Pharmacological Basis

Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1002/phar.1913 ◽

2017 ◽

Vol 37 (4) ◽

pp. 447-455 ◽

Cited By ~ 8

Author(s):

Jennifer C. Samp ◽

Min J. Joo ◽

Glen T. Schumock ◽

Gregory S. Calip ◽

A. Simon Pickard ◽

...

Keyword(s):

Pulmonary Disease ◽

Comparative Effectiveness ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Long Acting ◽

Beta2 Agonist

A Long-acting Muscarinic Antagonist （LAMA） Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:

The Showa University Journal of Medical Sciences ◽

10.15369/sujms.30.1 ◽

2018 ◽

Vol 30 (1) ◽

pp. 1-9

Author(s):

Koichi ANDO ◽

Akihiko TANAKA ◽

Sojiro KUSUMOTO ◽

Toshimitsu YAMAOKA ◽

Tohru OHMORI ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Beta 2 ◽

CE2 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY VERSUS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

Value in Health ◽

10.1016/j.jval.2018.09.014 ◽

2018 ◽

Vol 21 ◽

pp. S3

Author(s):

N. Benjamin ◽

A. Huerta ◽

C. Biswas ◽

M. Schroeder ◽

J. Whalen ◽

...

Keyword(s):

Cost Effectiveness ◽

Triple Therapy ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?

Cochrane Clinical Answers ◽

10.1002/cca.1708 ◽

2017 ◽

Author(s):

Adarsh Gupta

Keyword(s):

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Lifetime Benefits for Budesonide/Glycopyrrolate/Formoterol Fumarate versus Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2248 ◽

2021 ◽

Author(s):

E. De Nigris ◽

C. Treharne ◽

N. Brighton ◽

U. Holmgren ◽

A. Walker ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Long Acting ◽

Β2 Agonist ◽

Formoterol Fumarate